Offices Business Support and Services Available in Spanish

ProMéxico

ProMéxico



COORDINATION OF INSTITUTIONAL COMMUNICATION
Mexico City October 24th, 2017
Press release 92/2017

 

ProMexico leads seven companies to the most important pharmaceutical forum in the world

  • Mexico is the second largest market in Latin America in the pharmaceutical industry and is a major producer of high-tech medicine.
  • Major foreign investment in the Mexican pharmaceutical industry comes from Israel, United States, Germany and France.
Comunicado 92-17

Frankfort, Germany. From 24 to 26 October, ProMexico leads a business mission from seven pharmaceutical companies to CPhI Worldwide, the Fair of this most important industry in the world, with the aim of strengthening Mexican exports and the joint ventures in this sector.

The opening of the Pavilion of ProMéxico was in charge of the consul of Mexico in Frankfurt am Main, Ambassador Cecilia Villanueva Bracho; the Executive Director of ProMexico export projects, José Antonio Peral Vallejo; and the commercial Counsellor of ProMexico in Frankfurt, Nicole Inge Félix Huesca.

Institutions representing Mexico in this edition of CphI are ANCE, CECYC, Government of Coahuila, Sanfer laboratories, Neolpharma, Research Unit in Health and Zurich BIO.

The event will allow that Mexican institutions are promoted as providers of solutions, manufacturing contract and services. The Fair has different areas of display: InnoPack show pharmaceutical packaging and drug delivery systems; P-MEC has machinery, technology and pharmaceutical equipment, while Formulation of finished dose (FDF) will feature every aspect of the supply chain of finished dosage.

More than 42,000 pharmaceutical professionals from more than 150 countries and 2,500 exhibitors come together in this international platform. The event allows Mexican companies to establish new business relations after meeting with global partners and keep up-to-date on the latest trends in the industry.

Mexico is the second largest market in Latin America in the pharmaceutical industry, and is a major producer of high-tech medicines such as antibiotics, anti-inflammatory drugs and cancer treatments.

In 2015, Mexico was the leading exporter of Latin America with a total of 1,958 million dollars towards countries such as Switzerland, United States, Panama, Venezuela and Colombia. Mexico is highlighted as one of the most competitive countries in the manufacture of the pharmaceutical industry, positioning it as the main one on the American continent.

Major foreign investment in the Mexican pharmaceutical industry comes from Israel, United States, Germany and France. Mexico is an excellent destination for investment in the pharmaceutical industry thanks to the substantial improvements in regulatory, the normative framework of the pharmaceutical industry in Mexico is one of the most developed in Latin America, and was one of the first countries in the region in implementing specific norms for the development of biotechnological medicines.

—o0o—

Coordination of Institutional Communication
ProMéxico
promexico@promexico.gob.mx
Follow us on Twitter https://twitter.com/ProMexico
and Facebook https://www.facebook.com/ProMexicoOficial

About ProMéxico — ProMéxico is the Mexican government institution that supports Mexico's trade abroad and the internationalization of Mexican companies, and attracts foreign investment. Mexican business owners have access to a ProMéxico office in their place of origin, both in Mexico and abroad, bringing them closer to their potential buyers. Furthermore, foreign investors can reach every corner of the world through offices strategically located in areas that are key for world trade. For more information go to: www.promexico.gob.mx

Download Documento PDF